GLP-1 Myths: What the Evidence Actually Says

Few medication categories have generated as much conversation — and misinformation — as GLP-1-related medications.

Claims appear on social media every day:

"They're only diabetes drugs."

"GLP-1s make you lose all your muscle."

"The compounded version is exactly the same."

"Everyone gains all the weight back."

"They cause thyroid cancer."

Some claims contain a piece of truth but leave out important context.

Others are simply outdated.

Here are 10 common GLP-1 myths and what current evidence actually supports.

Medication information reviewed September 2026.

Educational information only. GoLean Horizon does not provide medical advice, prescribe medication, recommend a medication, or determine treatment eligibility. A licensed healthcare provider determines whether treatment is medically appropriate.

---

Myth 1: "GLP-1 Medications Are Only for Diabetes"

What the evidence says: False.

GLP-1 receptor agonists were originally developed and widely used for type 2 diabetes.

But several FDA-approved products now have indications beyond diabetes.

For example:

• Wegovy (semaglutide) is FDA approved for chronic weight management in certain people with obesity or overweight.
• Zepbound (tirzepatide) is approved for chronic weight management in certain adults.
• Foundayo (orforglipron) was approved in April 2026 for long-term weight reduction in certain adults.
• Wegovy also has certain cardiovascular and other approved indications.

A person does not necessarily need diabetes to have an FDA-approved indication for one of these medications.

The specific product and indication matter.

---

Myth 2: "All GLP-1 Medications Are Injections"

What the evidence says: No longer true.

Injectable GLP-1 medications remain common.

But oral options now exist.

Current FDA-approved oral weight-management options include:

• Wegovy tablets — semaglutide
• Foundayo — orforglipron

These are taken by mouth.

Their administration instructions are not identical.

For example, oral Wegovy has specific fasting and water requirements, while Foundayo does not require administration on an empty stomach.

For a detailed comparison, read:

Oral vs Injectable GLP-1 Options: What Should You Know?

---

Myth 3: "GLP-1 Drugs Are Basically Insulin"

What the evidence says: False.

GLP-1 receptor agonists are not insulin.

GLP-1 is a hormone involved in:

• appetite regulation
• food intake
• glucose-dependent insulin secretion
• glucagon regulation
• gastric emptying

Some medications activate only the GLP-1 receptor.

For example:

semaglutide → GLP-1 receptor

Tirzepatide works differently:

tirzepatide → GIP + GLP-1 receptors

These pathways can influence glucose metabolism, but the drugs themselves are not insulin.

For more:

Semaglutide vs Tirzepatide: What's the Difference?

---

Myth 4: "GLP-1 Medications Melt Fat"

What the evidence says: That's an oversimplification.

GLP-1-related medications do not directly "melt" fat.

They can influence:

• appetite
• hunger
• fullness
• food intake
• gastric emptying
• glucose regulation

When calorie intake decreases and body weight falls, the body can lose both:

fat mass

and

lean mass

The changes are biological consequences of weight reduction, not a drug selectively dissolving body fat.

---

Myth 5: "All the Weight You Lose Is Muscle"

What the evidence says: False — but lean-mass loss deserves attention.

Weight loss generally includes some lean tissue loss, whether weight reduction occurs through lifestyle intervention, medication, surgery, or other methods.

A body-composition substudy of the SURMOUNT-1 tirzepatide trial found that approximately:

75% of weight lost was fat mass

and

25% was lean mass

in the studied participants.

That does not mean every person will experience exactly that ratio.

And "lean mass" is not identical to skeletal muscle.

A 2026 systematic review cautioned that lean mass is not synonymous with skeletal-muscle loss or sarcopenia, and that current evidence on muscle preservation during GLP-1 treatment remains limited and heterogeneous.

Recent research also cautions against assuming that lean-mass measurements tell us everything about muscle strength, muscle quality, or physical function.

So both extremes are misleading:

"GLP-1s cause no lean-mass loss"

and

"GLP-1s make you lose all your muscle."

The better discussion involves nutrition, adequate protein when appropriate, resistance exercise, overall activity, age, health status, and individual monitoring.

---

Myth 6: "Everyone Loses the Same Amount of Weight"

What the evidence says: False.

Clinical trials report averages across groups.

They do not predict exactly what will happen to one individual.

People can respond differently because of factors such as:

• medication
• dose
• treatment duration
• side effects
• ability to continue treatment
• health conditions
• other medications
• eating patterns
• physical activity
• individual biology

If a clinical trial reports an average weight reduction of a certain percentage, some participants lost more.

Some lost less.

Some discontinued treatment.

An average is not a guarantee.

This is also why comparing medications only by a single headline percentage can be misleading.

---

Myth 7: "Compounded Semaglutide or Tirzepatide Is Exactly the Same as the FDA-Approved Product"

What the evidence says: False.

FDA-approved and compounded drugs are not the same regulatory category.

FDA-approved medications undergo FDA review for:

• safety
• effectiveness
• manufacturing quality

Compounded medications do not undergo FDA premarket review for safety, effectiveness, or quality.

FDA has also warned about dosing errors, adverse events, illegally marketed GLP-1 products, and certain compounded products using semaglutide salt forms that differ from the active ingredient used in FDA-approved semaglutide products.

As of May 31, 2026, FDA reported receiving hundreds of adverse-event reports associated with compounded semaglutide and compounded tirzepatide, while noting that causality cannot always be determined and that reporting for many compounders is not mandatory.

This does not mean compounding never has an appropriate role.

It means:

compounded does not mean FDA approved

and

compounded does not mean identical.

Ask:

• What exact medication am I receiving?
• Is it FDA approved?
• If compounded, why is compounding being used?
• Which pharmacy is preparing it?
• Is that pharmacy appropriately licensed?

---

Myth 8: "Once You Reach Your Goal Weight, You Can Stop the Medication and the Weight Will Automatically Stay Off"

What the evidence says: Research shows substantial weight regain can occur after treatment is stopped.

This does not mean every person regains every pound.

But randomized withdrawal studies show that regain can be substantial.

In an extension of the STEP 1 semaglutide trial, participants who stopped semaglutide regained about two-thirds of their previous weight loss over the following year, on average.

Research involving tirzepatide has shown a similar general pattern.

In SURMOUNT-4, people who stopped tirzepatide experienced substantial weight regain, while those who continued treatment maintained and added to their earlier weight reduction.

A 2026 analysis also found that most participants who had tirzepatide withdrawn regained at least 25% of the weight they had previously lost within a year.

These findings do not mean every patient must take the same medication forever.

They do show that obesity can require ongoing management.

Decisions about continuing, changing, tapering, or stopping treatment should be individualized with a healthcare professional.

---## Myth 9: "FDA Found That GLP-1 Drugs Cause Suicidal Thoughts"

What the evidence says: FDA's current conclusion is the opposite.

FDA investigated reports of suicidal thoughts and behavior associated with GLP-1 receptor agonists.

After reviewing available evidence, FDA announced in January 2026 that it did not identify an increased risk of suicidal ideation or behavior associated with GLP-1 receptor agonist medications.

FDA therefore requested removal of the suicidal-behavior and ideation warning from labeling where it had appeared for:

• Saxenda
• Wegovy
• Zepbound

This is a good example of why older social-media posts or articles can become outdated.

Safety surveillance continues even after medications reach the market.

Anyone experiencing suicidal thoughts or major mood changes should still seek appropriate medical help regardless of what medication they are taking.

---

Myth 10: "The Thyroid Cancer Warning Means GLP-1 Drugs Have Been Proven to Cause Thyroid Cancer in Humans"

What the evidence says: That is not what the warning says.

Several GLP-1-related products carry an FDA boxed warning about:

thyroid C-cell tumors

For semaglutide and tirzepatide, thyroid C-cell tumors occurred in rodents.

FDA labeling states that it is unknown whether these medications cause thyroid C-cell tumors, including medullary thyroid carcinoma, in humans because the relevance of the animal findings to humans has not been determined.

That does not mean the warning should be ignored.

Products such as Wegovy and Zepbound are contraindicated in people with:

• a personal history of medullary thyroid carcinoma
• a family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2, or MEN 2

So both statements below go too far:

"GLP-1 medications definitely cause thyroid cancer in people."

and

"The thyroid warning doesn't matter."

The accurate statement lies between them:

There is an important FDA warning based substantially on animal findings, while a causal thyroid-cancer risk in humans has not been established.

---

Bonus Myth: "Lifestyle Doesn't Matter Once You're Taking a GLP-1"

What the evidence says: FDA-approved weight-management indications still include lifestyle measures.

FDA approvals for medications such as Wegovy, Zepbound, and Foundayo specify their use together with measures such as:

• reduced-calorie diet
• increased physical activity

Medication can influence hunger, appetite, food intake, and metabolism.

But it does not make:

• nutrition
• physical activity
• strength
• hydration
• sleep
• follow-up care

irrelevant.

Those factors are also important for overall health beyond what happens on the scale.

---

Myth vs Evidence at a Glance

---

Why GLP-1 Misinformation Spreads So Easily

There are several reasons.

The science changes quickly

New:

• medications
• formulations
• doses
• indications
• safety reviews

continue to appear.

Information accurate two years ago may already be incomplete.

Brand names create confusion

For example:

Wegovy and Ozempic both contain semaglutide

but they are not simply interchangeable labels for the same FDA indication.

Likewise:

Zepbound and Mounjaro both contain tirzepatide

but their approved indications differ.

Clinical-trial averages become social-media guarantees

A group average gets transformed into:

"You will lose X%."

That is not how clinical-trial data should be interpreted.

Risk gets stripped of context

A boxed warning may become:

"This drug causes cancer."

An adverse-event report may become:

"FDA proved the medication caused it."

Neither interpretation necessarily follows from the evidence.

---

Five Questions to Ask When You Hear a GLP-1 Claim

Before believing or sharing a claim, ask:

1. Is the claim about a specific medication or the entire category?
2. Is it based on an FDA label, clinical trial, observational study, case report, or social-media anecdote?
3. Was the medication FDA approved or compounded?
4. Does the evidence show association or actual causation?
5. How recent is the information?

This matters particularly in a field changing as quickly as GLP-1 treatment.

---

Where Should You Get Medication Information?

Useful sources include:

• FDA prescribing information
• FDA drug-safety communications
• licensed healthcare professionals
• pharmacists
• peer-reviewed clinical research

Be more cautious with claims based primarily on:

• testimonials
• influencer videos
• screenshots without sources
• advertisements
• anonymous posts
• dramatic before-and-after examples

Personal experiences can be meaningful.

But one person's experience cannot establish what a medication will do for everyone else.

---

Provider Choice Still Matters

Medication information is only part of the picture.

When comparing GLP-1 telehealth providers, ask:

• Who reviews my health information?
• Which medication options are offered?
• Is the medication FDA approved or compounded?
• Which pharmacy is used?
• How does follow-up work?
• What does the price include?
• Can I contact a clinician with questions?

Read:

7 Questions to Ask Before Choosing a GLP-1 Provider

To understand what to expect after you sign up with a telehealth provider:

What Happens After Signup? A GLP-1 Telehealth Walkthrough

---

The Bottom Line

GLP-1 medications are real prescription therapies with:

documented benefits

known risks

remaining uncertainties

and

rapidly evolving evidence.

The most accurate view is rarely found at either extreme.

They are not:

miracle drugs with no risks

and they are not:

automatically dangerous medications with no legitimate medical role.

Current evidence supports a more useful approach:

Know the exact medication.

Understand the FDA-approved indication.

Distinguish approved from compounded products.

Understand benefits and risks.

Treat clinical-trial averages as averages — not promises.

Use current evidence rather than viral claims.

And let an appropriately licensed healthcare professional determine whether treatment is medically appropriate for you.